These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23331791)

  • 1. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
    Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
    J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
    Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
    Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
    Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of liposomal topotecan for use in treating neuroblastoma.
    Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
    Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging tumor resistance with less toxic, more effective drug combinations: an example from neuroblastoma.
    Gambacurta A; Raschellà G
    Cell Death Dis; 2018 Jun; 9(6):686. PubMed ID: 29880790
    [No Abstract]   [Full Text] [Related]  

  • 9. Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activity.
    Orr WS; Denbo JW; Saab KR; Ng CY; Wu J; Li K; Garner JM; Morton CL; Du Z; Pfeffer LM; Davidoff AM
    PLoS One; 2013; 8(2):e51309. PubMed ID: 23408929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer.
    Cotino-Nájera S; Herrera LA; Domínguez-Gómez G; Díaz-Chávez J
    Front Pharmacol; 2023; 14():1287505. PubMed ID: 38026933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy as a Promising Way to Fight Oral Cancer.
    Silva JPN; Pinto B; Monteiro L; Silva PMA; Bousbaa H
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies.
    Banchi M; Fini E; Crucitta S; Bocci G
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.
    Nishii K; Ohashi K; Watanabe H; Makimoto G; Nakasuka T; Higo H; Ninomiya K; Kato Y; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Oncol Lett; 2021 Sep; 22(3):639. PubMed ID: 34386061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors.
    Casillas AL; Chauhan SS; Toth RK; Sainz AG; Clements AN; Jensen CC; Langlais PR; Miranti CK; Cress AE; Warfel NA
    Oncogene; 2021 Aug; 40(32):5142-5152. PubMed ID: 34211090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
    Fukuda N; Takahashi S
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34068664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-199a-5p-HIF-1α-STAT3 Positive Feedback Loop Contributes to the Progression of Non-Small Cell Lung Cancer.
    Yang X; Zheng Y; Tan J; Tian R; Shen P; Cai W; Liao H
    Front Cell Dev Biol; 2020; 8():620615. PubMed ID: 33681184
    [No Abstract]   [Full Text] [Related]  

  • 17. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.
    Moisan F; Oucherif S; Kaulanjan-Checkmodine P; Prey S; Rousseau B; Bonneu M; Claverol S; Gontier E; Lacomme S; Dousset L; Couffinhal T; Toutain J; Loot M; Cario-André M; Jullié ML; Léauté-Labrèze C; Taieb A; Rezvani HR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33558238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Antiangiogenic Therapies in Pediatric Solid Tumors.
    Ollauri-Ibáñez C; Astigarraga I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeting therapies for neuroblastoma: Progress and challenges.
    Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
    Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing preclinical models of neuroblastoma: driving therapeutic testing.
    Ornell KJ; Coburn JM
    BMC Biomed Eng; 2019; 1():33. PubMed ID: 32903387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.